Public Procurement of Medicines in Europe: Key Findings and Best Practices
Experts in the Pharmacoeconomics Department recently conducted a study on the best practices in the public procurement of medicines. Commissioned by the European Commission, this study aims to improve access to medicines, affordability, availability, and more.
Public procurement of medicines can improve access, foster competition, and address important policy objectives. This study mapped and analyzed PPM practices across 32 European countries, revealing some fascinating insights.
Findings include:
- Different organizational forms of procurement, ranging from facility-based to centralized procurement.
- Use of various procedures and techniques, including the Most Economically Advantageous Tender
- Specific forms of procurement in the hospital sector
- Impacts on policy objectives, such as access to medicines and environmental protection
- Best practices for optimizing PPM in Europe
Discover the full report for a comprehensive understanding of PPM practices in Europe on the below link. Let’s work together to ensure affordable and accessible medicines for all!
Recent Posts
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex Dynamics
Pharmaceutical innovation funding in the UK faces scrutiny amid industry claims that low NHS spending deters investments, but this narrative overlooks key drivers like scientific talent, tax incentives, and operational efficiencies rather than drug prices alone. A recent Lancet article critiques ...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
Darolutamide prostate cancer treatment has received a major endorsement from the National Institute for Health and Care Excellence (NICE), which issued final draft guidance recommending darolutamide combined with androgen deprivation therapy (ADT) for adults with hormone-sensitive metastatic pros...
Rethinking Health Technology Assessment: Evolving Economic Evaluations for Fair Resource Allocation
Health technology assessment plays a pivotal role in resource-constrained healthcare systems. How can organizations like NICE, ICER, and Canada's Drug Agency better incorporate novel value elements into economic evaluations? They can do so by adopting a principled framework that evolves beyond tr...